A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
Sponsor: Bristol-Myers Squibb
Listed as NCT04943900, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 17 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
May 2025 — Sep 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 12 earlier versions
-
Jan 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .